Show simple item record

dc.contributor.authorScagliotti, G V
dc.contributor.authorVynnychenko, I
dc.contributor.authorPark, K
dc.contributor.authorIchinose, Y
dc.contributor.authorKubota, K
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorPirker, R
dc.contributor.authorGaliulin, R
dc.contributor.authorCiuleanu, T
dc.contributor.authorSydorenko, O
dc.contributor.authorDediu, M
dc.contributor.authorPapai-Szekely, Z
dc.contributor.authorBanaclocha, N M
dc.contributor.authorMcCoy, S
dc.contributor.authorYao, B
dc.contributor.authorHei, Y J
dc.contributor.authorGalimi, F
dc.contributor.authorSpigel, D R
dc.date.accessioned2012-11-09T14:06:51Z
dc.date.available2012-11-09T14:06:51Z
dc.date.issued2012-08-10
dc.identifier.citationInternational, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. 2012, 30 (23):2829-36 J Clin Oncolen_GB
dc.identifier.issn1527-7755
dc.identifier.pmid22753922
dc.identifier.doi10.1200/JCO.2011.41.4987
dc.identifier.urihttp://hdl.handle.net/10541/251563
dc.description.abstractWe evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIndoles
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNiacinamide
dc.subject.meshPaclitaxel
dc.subject.meshReceptors, Vascular Endothelial Growth Factor
dc.subject.meshYoung Adult
dc.titleInternational, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.en
dc.typeArticleen
dc.contributor.departmentUniversity of Turin, S. Luigi Hospital, Turin, Italy.en_GB
dc.identifier.journalJournal of Clinical Oncologyen_GB
refterms.dateFOA2020-04-21T10:16:00Z
html.description.abstractWe evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma.


Files in this item

Thumbnail
Name:
271550.pdf
Size:
233.6Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record